Another study conducted a longitudinal tracking of 45 patients with NSCLC and evaluated the PD-L1 expression on CTCs during nivolumab administration and found that, at week 8, patients whose PD-L1 positivity rates were ≥ 7.7% had significantly longer PFS (P < 0.01) [32]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.